Mitochondria play an important role in controlling the life and death of a cell. Consequently, mitochondrial dysfunction leads to a range of human diseases such as ischemia -reperfusion injury, sepsis, and diabetes. Although the molecular mechanisms responsible for mitochondriamediated disease processes are not fully elucidated yet, the oxidative stress appears to be critical. Accordingly, strategies are being developed for the targeted delivery of antioxidants to mitochondria. In this review, we shall briefly discuss cellular reactive oxygen species metabolism and its role in pathophysiology; the currently existing antioxidants and possible reasons why they are not effective in ameliorating oxidative stressmediated diseases; and recent developments in mitochondrially targeted antioxidants and their future promise for disease treatment. D
Introduction
There is a continuing search for better and more effective antioxidants. The recent recognition of mitochondria as an arbiter of the life and death of cells has drawn awareness to the need to develop antioxidants and other cytoprotective agents targeted to mitochondria. Physiologically, mitochondria perform a variety of key cellular regulatory processes, including ATP production, intracellular Ca 2+ regulation, reactive oxygen species (ROS) generation and detoxication, and apoptosis [1] . Mitochondria use approximately 90% of the consumed O 2 for oxidative phosphorylation and ATP synthesis. Thus, the proteins involved in the mitochondrial electron transport chain are probable sites for ROS generation. Intracellular glutathione, glutathione peroxidase, glutathione transferases, catalase, superoxide dismutase, and a variety of other antioxidant defenses keep ROS concentrations in check, which allows cells to function homeostatically and to prevent oxidative stress [2] [3] [4] [5] [6] . A shift in the balance between ROS generation and destruction to overproduction or decreased detoxication is associated with chronic diseases [7] .
During the last 5 years, research effort in developing mitochondria-targeted antioxidants has increased steadily. This is exemplified by recent studies showing that triphenylphosphonium-based antioxidants and amino acid-and peptide-based antioxidants protect mitochondria against oxidative insult. One can envision that the future efforts in exploiting the unique biophysical and biochemical properties of mitochondria for the targeted delivery of cytoprotective agents will increase rapidly.
Cellular mechanisms of ROS generation
The etiology of a range of diseases is associated with the generation of excess ROS. Steady-state maintenance of ROS/ antioxidant ratio is, however, essential for cell signaling. ROS generated in cells include the superoxide anion radical (O 2 SÀ ), hydrogen peroxide (H 2 O 2 ), hypochlorous acid (HOCl), hydroxyl radical (OH S ), and singlet oxygen ( 1 O 2 ). These ROS are formed as a consequence of endogenous enzymatic and nonenzymatic reactions within the cell and within mitochondria. ROS may also be formed in response to external stimuli and chemicals. Cellular sources of ROS are shown in Fig. 1 .
ROS are generated by biochemical reactions in the cell. SÀ [8] . Moreover, the TCA cycle enzymes a-ketoglutarate dehydrogenase and the pyruvate dehydrogenase complex also generate O 2 SÀ and H 2 O 2 [9] . O 2 SÀ is also generated by NADPH oxidase, which is found in phagocytic and nonphagocytic macrophages [10] , and by xanthine dehydrogenase/oxidase (XO, Fig. 1 ) [11] . H 2 O 2 peroxide is produced by mitochondrial monoamine oxidase (MAO, Fig. 1 ) [12] and by the superoxide dismutase (MnSOD and Cu/ZnSOD, Fig. 1 )-catalyzed dismutation of O 2 SÀ [13] . In addition, peroxisomal acyl-CoA oxidases also generate H 2 O 2 [14] . The myeloperoxidase-catalyzed generation of hypochlorous acid is an important line of defense against invading microorganisms (MPO, Fig. 1 ) [15] .
There is no known enzymatic route to hydroxyl radical, but it is produced by the Haber-Weiss reaction in the presence of transition metals, particularly iron.
1 O 2 may be formed by photodynamic processes or from the reaction of HOCl with H 2 O 2 .
Although not the focus of this review, reactive nitrogen species (RNS, Fig. 1 ) have also been implicated in cell damage and death. Nitric oxide synthase (NOS, Fig. 1 ) catalyzes the synthesis of the radical species nitric oxide (NO S , Fig. 1 ), which may react with O 2 SÀ to give peroxy- Fig. 1 ). ROS generation may also be associated with external stimuli. UV and high-energy irradiation (UV, Fig. 1 ), the metabolism of some xenobiotics, air pollutants (O 3 , Fig. 1 ), and the redox cycling of quinones (Q, Fig. 1 ) and nitroaromatics are all associated with ROS generation.
The balance between these sources of ROS depends on the physiologic and pathophysiologic states of the organism, and it is often difficult to pinpoint the source of ROS generation. It is, however, known that ROS exert important regulatory functions [16] . Hence, a basal or tonal concentration of ROS, especially at the level of the mitochondrion, is essential for basic cell signaling processes. In other words, all ROS are not created equal, and compartmentalization and concentration gradients are highly important. Although a full discussion of ROS-dependent cell signaling is beyond the scope of this review, it is important to recognize that the abolishment all cellular ROS by vigorous use of antioxidants may not be beneficial and, indeed, may prove harmful. The requirement for a basal ROS tone for cell signaling may explain why many antioxidant-based therapies have failed. A more subtle approach is required, in which specific populations of ROS are targeted; hence, the current discussion on mitochondrial targeting of antioxidants.
Oxidative stress in disease etiology
Traditionally, mitochondrial diseases have focused on mitochondrial respiratory-chain diseases associated with mutations of mitochondrial DNA [17] . For instance, a maternal inheritance of a point mutation in the complex I gene (ND4) causes Leber's hereditary optic neuropathy (LHON) [18] . The diseases that result from familial mitochondrial DNA deletions and mutations are not as common as those that result from nuclear DNA defects. This may be because mitochondria contain several copies of their genome; hence, continuous fusion of mitochondria mixes the modified genes with the normal genes so that deleterious effects are reduced. Moreover, the continuous fission of mitochondria increases the likelihood that modified mitochondrial genes are removed by autophagy [19] .
The recent realization that acute and chronic stresses to the cells leads to structural and functional impairments of mitochondria has redefined the role of mitochondria in disease etiology. Mitochondrial dysfunction triggers signaling cascades for necrosis and apoptosis of cells and results in organ failure and diseases. Although the list of mitochondria-related diseases is growing rapidly and includes, among others, cancer, heart failure, diabetes, obesity, stroke, neurodegenerative diseases, and aging, they all share the common features of disturbances of mitochondrial Ca 2+ , ATP, or ROS metabolism [20] . For instance, a number of experimental observations indicates that cancer cells show noticeable variation in their metabolic regulation and mitochondrial morphology and physiology compared with normal cells [21, 22] . Interestingly, antioxidants have been used to increase efficacy of anticancer therapeutic agents by reducing their adverse effects on normal cells [23] . Similarly, studies show that mitochondrial dysfunction contributes to the progression of neurogenerative diseases, e.g., Parkinson's disease, and stroke [24, 25] . Myocardial ischemiareperfusion injury also results in mitochondrial Ca 2+ overload that subsequently leads to uncontrollable ROS generation and opening of mitochondrial permeability transition pore [20] . Therefore, compounds that minimize mitochondrial Ca 2+ overload, decrease mitochondrial ROS accumulation, and improve mitochondrial energy production all have the potential for treating the above-mentioned diseases.
Types of antioxidants and mechanisms of antioxidant actions
The term antioxidant is not readily defined and, as used in the literature, may refer to a range of compounds with a range of mechanisms of action. Halliwell [26] has proposed this useful definition: ''an antioxidant is any substance that, when present at low concentrations compared to those of an oxidizable substrate, significantly delays or prevents oxidation of that substrate.'' There is an abundance of oxidizable substrates in the cell, including proteins, lipids, carbohydrates, and DNA. Thus, antioxidants may function to prevent the formation of or to detoxify free radicals, to scavenge ROS or their precursors.
Types of antioxidants include, for example, antioxidant vitamins (e.g., ascorbic acid, a-tocopherol, h-carotene), inorganic antioxidants (e.g., selenium), synthetic antioxidants (e.g., butylated hydroxyanisole [BHA], butylated hydroxytoluene [BHT], propyl gallate, 2,4,6-trimethylphenol), and a range of plant-derived polyphenols.
Mechanisms of antioxidant action can best be understood in the context of their chemical and biochemical effects on ROS. Lipid-derived oxygen-and carbon-centered free radicals are a major class of oxidants. Three processes are involved in the formation of lipid-derived free radicals: initiation, propagation, and termination. Chain-breaking antioxidants interrupt this process by preventing propagation of the radical chain or by terminating the radical chain. S is known; hence, the prevention of its formation is a critical antioxidant process. Similarly, no detoxication system for HOCl is known.
In summary, a range of natural and synthetic antioxidants is available, and their mechanisms of action are mostly known. Because of the presumed role of oxidative stress in cardiovascular disease and a number of other chronic diseases, a number of human clinical trials have been conducted with antioxidants, particularly vitamin E. The results of these clinical trials have, however, failed to show consistent and significant clinical benefit, and there is some concern that high-dose vitamin E supplementation may be harmful [27] . It is possible that carefully designed and conducted randomized clinical trials may show that antioxidant supplementation is beneficial. One plausible explanation for the failure of antioxidants to show beneficial effects is that these antioxidants do not accumulate preferentially in the mitochondria, the major site of ROS generation.
Antioxidants targeted to mitochondria
Mitochondria are attractive targets for drug-delivery strategies because of their roles in cellular energy metabolism, programmed (apoptotic) cell death, Ca 2+ homeostasis, and cell signaling. Moreover, mutations in mitochondrial DNA are associated with a range of human diseases, again making mitochondria attractive targets for mitochondrial gene therapy. Hence, there is considerable interest in developing strategies to target small and large molecules with therapeutic potential to mitochondria (for reviews, see [28 -30] ).
A range of possibilities is available for the selective delivery of drugs to mitochondria, including targeting based on biophysical properties of mitochondria, e.g., the high negative internal potential, targeting based on the unique mitochondrial localization of enzymes that catalyze the release of drugs from prodrugs, and targeting based on transporter-dependent delivery of prodrugs (Fig. 2) .
The mitochondrial respiratory chain participates in transfer of electron to O 2 . This electron transport generates a proton gradient that is used to drive the production of ATP by ATP synthase. Thus, a negative potential of 150-180 mV is generated across the inner mitochondrial membrane. (The mitochondrial outer membrane is permeable to small molecules, and thus the inner membrane represents the major barrier for drug delivery to the mitochondria.) This high potential gradient across the mitochondrial inner membrane can be exploited to deliver lipophilic cations to mitochondria. According to the Nernst equation, a 61.5-mV hyperpolarization in the mitochondria membrane potential should result in a 10-fold increase in the concentration of the lipophilic monovalent cations inside mitochondria at equilibrium. Therefore, the lipophilic cations may accumulate in the mitochondrial matrix at concentrations 100-to 1000-fold higher than in the cytosol. This knowledge was adopted to develop cationic compounds, such as rhodamine 123 and triphenylphosphonium (TPP + ) for mitochondrial membrane potential determinations. Murphy and coworkers have extended this concept to develop a series of cationic antioxidants that preferentially accumulate in mitochondria [31] .
The aim of this section of the review is to discuss mitochondrially targeted antioxidants. The mitochondrial targeting of therapeutic agents is, to be sure, not limited to antioxidant compounds, and Weissig and coworkers [30] have nicely summarized the scope of strategies for targeting low molecular-weight compounds to mitochondria.
Triphenylphosphonium-based, mitochondrially targeted antioxidants
MitoVit E was synthesized to test the concept that the delivery of an antioxidant to mitochondria should selectively prevent mitochondrial oxidative damage [32] . MitoVit E is rapidly taken up by energized mitochondria, and the uptake persists for at least 15 min. As expected, dissipation of the mitochondrial membrane potential with FCCP results in the rapid loss of MitoVit E from mitochondria. Accumulation ratios (mitochondria/cytoplasm) of 5000-6000 are achieved after incubating mitochondria with 1 -20 AM MitoVit E; uptake decreases at 50 AM MitoVit E (Fig. 3) .
MitoVit E protects isolated rat liver mitochondria from iron/ ascorbate-and tert-butylhydroperoxide-induced oxidative damage, as measured by decreased lipid peroxidation (thiobarbituric acid reactive species). The protection against tert-butylhydroperoxide-induced oxidative damage afforded by MitoVit E was abolished when the mitochondrial membrane potential was dissipated with FCCP, and the analog triphenylphosphonium bromide failed to provide protection against oxidative damage.
The cellular uptake of MitoVit E was studied in human osteosarcoma 143B cells. Uptake is rapid, and a steady-state concentration is achieved in approximately 60 min, but less (¨60%) uptake is observed in U 0 cells, which lack mitochondrial DNA, derived from the 143B cell line. The distribution of MitoVit E was studied in cells fractionated by digitonin treatment; approximately 91% of the accumulated MitoVit E was colocalized with the matrix enzyme citrate synthase. Finally, MitoVit E was cytotoxic at concentrations greater than 50 AM.
The effect of MitoVit E on mitochondrial ROS in TNFinduced apoptosis has been investigated in Jurkat and U937 cells [33] . MitoVit E reduces H 2 O 2 -induced caspase-3 activity in Jurkat cells. The cleavage and activation of caspase-8 after incubation with TNF were not affected by MitoVit E, but the activation of caspase-3 was increased. In addition, increased cleavage of Bid and an increased release of cytochrome c from mitochondria were observed in cells incubated with TNF in the presence of MitoVit E. Further studies showed that MitoVit E accelerated TNF-induced apoptosis by increasing the nuclear localization of NF-nB. These findings demonstrate that mitochondrial ROS generation is a component of the TNF signal-transduction pathway during apoptosis.
Friederich ataxia (FRDA) is an inherited nervous-system disease that is associated with the decreased expression of the mitochondrial protein frataxin. Frataxin is involved in mitochondrial iron homeostasis, and decreased expression of frataxin leads to oxidative stress and decreased mitochondrial respiratory chain function [34] . Further evidence for a role of oxidative stress in FRDA is the finding that long-term treatment of FRDA subjects with coenzyme Q and vitamin E leads to improvement in mitochondrial energy synthesis and in cardiac function [35] . MitoVit E prevents oxidative-stress-induced cell death in cultured fibroblasts from FRDA subjects [36] . Indeed, MitoVit E is 350-fold more potent than the water-soluble vitamin E analog trolox, indicating that mitochondrially targeted antioxidants may ultimately prove useful in the treatment of FRDA.
The effectiveness of MitoVit E in preventing oxidative damage to mitochondria and blocking apoptosis has been studied in bovine aortic epithelial cells (BAEC) [37] . MitoVit E (1 AM) decreased H 2 O 2 -and lipid peroxidation-induced ROS generation; in addition, MitoVit E inhibited cytochrome c release, caspase-3 activation, DNA fragmentation, inactivation of complex I and aconitase, overexpression of transferrin receptor, and mitochondrial iron uptake and restored the mitochondrial membrane potential and proteosomal activity.
MitoQ, a mixture of 10-(6V-ubiquinolyl)decyltriphenylphosphonium bromide (Fig. 3) and 10-(6V-ubiquinonyl)decyltriphenylphosphonium bromide
Because of the known antioxidant properties of ubiquinone, studies were undertaken to prepare and test a triphe-nylphosphonium-based, mitochondrially targeted mixture of ubiquinol (mitoquinol) and ubiquinone (mitoquinone), MitoQ [38] .
Mitoquinone is reduced to mitoquinol and mitoquinol is oxidized to mitoquinone by beef heart mitochondrial membranes, indicating redox cycling of the targeted compounds analogous to endogenous ubiquinone. MitoQ is rapidly taken up by energized mitochondria; the maximum accumulation ratio of MitoQ is approximately 500 -600. The addition of FCCP results in the efflux of MitoQ from mitochondria. The intramitochondrial localization of MitoQ was also studied; the data indicate that MitoQ is taken up by energized mitochondria and is adsorbed onto the matrix face of the inner mitochondrial membrane. MitoQ is also taken up by 143B osteosarcoma cells over 20 -40 min, and addition of FCCP reduces uptake. Further distribution studies showed that about one half of the MitoQ taken up by cells was localized in the mitochondrial fraction.
Strategies for Mitochondrially Targeted Drugs
Concentrations of MitoQ greater than 25 AM resulted in a loss of the mitochondrial membrane potential, whereas 10 AM MitoQ had little effect. MitoQ was cytotoxic to 143B cells at concentrations of 25 -50 AM.
MitoQ prevents the H 2 O 2 -induced oxidation of cis-parinaric acid and the ferrous iron-induced formation of malondialdehyde. MitoQ (1 AM) blocks H 2 O 2 -induced caspase activation and apoptotic cell death in Jurkat cells, but has no effect on staurosporine-induced apoptosis in Jurkat cells or TNF-ainduced apoptosis in WEHI 164 cells.
Studies were conducted to determine the role of hydrophobicity in the uptake of MitoQ analogs by mitochondrial membranes [39] . In these studies, analogs were prepared in which the length of the hydrocarbon chain separating the triphenylphosphonium and ubiquinol moieties was 3, 5, 10, and 15 methylene units. As expected, the octan-1-ol/saline partition coefficient increased as the chain length was increased. Similarly, the mitochondrial uptake ranged from negligible for MitoQ 3 to nearly complete for MitoQ 15 . Although all analogs showed antioxidant effects, MitoQ 10 and MitoQ 15 showed the highest efficacy in blocking ferrous iron-induced lipid peroxidation.
The studies on chain-length analogs of MitoQ have been extended to investigate their interactions with the mitochondrial respiratory chain and ROS [40] . MitoQ 10 failed to restore respiration in Saccharomyces cervisiae strain DCOQ2, which is not competent to synthesize CoQ, whereas exogenous CoQ 6 restored respiration; this is attributed to a failure of complex III to oxidize MitoQ analogs. MitoQ analogs are reduced by complex II and glycerol 3-phosphate dehydrogenase, and the rate of reduction increases as the chain length is increased from MitoQ was used to investigate nucleotide-sensitive mitochondrial proton transport through uncoupling proteins (UCP) [41] . Superoxide-induced uncoupling was prevented by MitoQ (and MitoVit E), but not by the untargeted antioxidants ubiquinone, decylubiquinone, vitamin E, or trolox.
Because of the role of oxidative damage telomere shortening and, thus in senescence and aging, the effect of MitoQ on telomere shortening was investigated [42] . MitoQ (50 -100 nM) is cytostatic to MRC-5 fibroblasts, and concentrations of The effect of MitoQ on cardiac ischemia -reperfusion injury, which is associated with mitochondrial oxidative damage, has been investigated a rat model [43] . Rats were given drinking water that contained 500 AM MitoQ for 14 days; as observed previously, no treatment-related effects on behavior or gross pathology were noted [44, 45] . At the end of the treatment period, the hearts were removed and perfused in a Langendorff apparatus, which allowed assessment of ventricular contractile function and left ventricular developed pressure (LVDP). After equilibration, the hearts were subjected to 30 min of global zero-flow ischemia followed by normoxic reperfusion. MitoQ affords significant protection against ischemia -reperfusion-induced decreases in LVDP, left ventricular pressure against time (dP/dt max), coronary blood flow, and heart rate, whereas little or no benefit was found with the nontargeted ubiquinone (Q 3 OH) or triphenylmethylphosphonium bromide. The protective effects of MitoQ were confirmed by morphological analysis. Mitochondrial function was assessed in heart mitochondria from control and MitoQ-treated rats. MitoQ protects against the ischemia -reperfusion-induced decreases in the respiratory control ratio (RCR), damage to complex I, and decreases in aconitase activity. The amount of MitoQ in the hearts of treated rats is approximately 20 pmol MitoQ/g wet weight, which corresponds to a concentration of 100-200 nM MitoQ. (Fig. 3) Nitrones and phenyl tert-butylnitrone (PBN) in particular have been investigated as neuroprotective agents and antioxidants. Although PBN reacts readily with carbon-centered radicals, it apparently does not function as a chain-breaking antioxidant and does not react with superoxide [46] . PBN exerts protective effects in a range of animal models, including protection against endotoxin shock, protection against ischemia -reperfusion injury, and neuroprotection in experimental models of neurodegeneration and also increases the life span of mice and rats [47, 48] . The mechanism whereby PBN exerts these effects has often been attributed to an antioxidant effect, but some evidence supports a role for PBN in inhibiting the expression of proinflammatory genes and cytokines.
Because of the selectivity of PBN in reacting with carboncentered radicals, a mitochondrially targeted analog, i.e., MitoPBN, was prepared to dissect the roles of ROS in the activation of uncoupling proteins (UCPs) [49] ; previous studies show that MitoVit E and MitoQ block superoxide-induced activation of UCPs [41] . MitoPBN was rapidly taken up by (Fig. 3) Ebselen is an organoselenium compound that shows antioxidant effects through its glutathione peroxidase-like action [50] . It has been used extensively to study oxidative phenomena in experimental systems and has been used in clinical studies of stroke and inflammatory diseases. To explore the peroxidase-mimetic effects of ebselen in mitochondria, MitoPeroxidase, a mitochondrially targeted analog of ebselen, was prepared [51] . MitoPeroxidase and ebselen (50 AM) inhibit mitochondrial respiration and decrease the mitochondrial membrane potential. The binding of MitoPeroxidase to isolated mitochondria was studied with a TPP + -sensitive electrode. Binding of MitoPeroxidase to mitochondria is rapid, and the addition of deenergized mitochondria decreases the concentration of free MitoPeroxidase. To investigate whether binding to mitochondria is associated with the selenol (R-SeH) form of MitoPeroxidase, the selenol was reacted with iodoacetamide to block the selenol group and give carboxyamidomethylated MitoPeroxidase (CAM-MitoPeroxidase). (Studies with bovine heart mitochondrial membranes showed that MitoPeroxidase reacts with protein thiols in the membranes.) CAM-MitoPeroxidase also became bound to mitochondria, but to a lesser extent than that observed with MitoPeroxidase, and the uptake of CAM-MitoPeroxidase is reversed by addition of FCCP. Also, MitoPeroxidase and ebselen degrade phospholipid hydroperoxides and prevent Fe 2+ /H 2 O 2 -induced lipid peroxidation in intact mitochondria, but these antioxidant effects require glutathione or thioredoxin to generate the selenol form of MitoPeroxidase and ebselen. Both MitoPeroxidase and ebselen decrease 2-deoxyglucose-or H 2 O 2 -induced caspase-3-associated apoptosis in RBL-2H3 cells.
5.2.
Amino acid-and peptide-based, mitochondrially targeted antioxidants 5.2.1. SS tetrapeptides (Fig. 4) The SS tetrapeptides are aromatic -cationic peptides that bear the structural motif of alternating aromatic and basic amino acid residues along with a 2V,6V-dimethyltyrosine (Dmt) residue [52] . The antioxidant properties of these tetrapeptides apparently stem from the presence of Dmt; the related compound 3,5-dimethylphenol is a known phenolic antioxidant [53] . The SS tetrapeptides were originally prepared in an attempt to develop centrally acting opioid analgesics [54 -56] mitochondria showed that about 85% of [ 3 H]SS-02 was present in the mitoplast (inner mitochondrial membrane and matrix).
A panel of in vitro experiments showed that SS-31 and SS-02 protect neuronal N 2 A cells from tert-butylhydroperoxideinduced ROS generation and cytotoxicity, Caco-2 cells against 3-nitropropionic acid-induced mitochondrial depolarization, and isolated mitochondria from hydrogen peroxide-induced ROS generation and calcium-induced swelling and mitochondrial permeability transition (MPT); SS-20 lacks antioxidant properties in these experiments. Finally, SS-02 and SS-31 protect against the loss of contractile force induced by 30 min of global ischemia in the isolated perfused guinea pig heart, whereas SS-20 failed to prevent the loss of contractile function associated with reperfusion. These studies show that these cellpermeable tetrapeptides are effective antioxidants in a range of in vitro studies. Moreover, these small peptides do not require the attachment of a cationic molecule to be accumulated preferentially in mitochondria. Thus they may have the advantage in exerting effective antioxidant action in depolarized mitochondria.
Choline esters of glutathione and N-acetyl-l-cysteine
Glutathione (l-g-glutamyl-l-cysteinylglycine) is the most abundant nonprotein thiol in cells. Glutathione plays a critical role in antioxidant defense mechanisms and in the detoxification of endobiotic and xenobiotic electrophiles [57] . Mitochondria are, however, not competent to synthesize glutathione, and glutathione is transported from the cytoplasm to the mitochondria by a high-affinity, low capacity transporter (K m å 60 AM, V max å nmol/min/mg protein) [58] . Present evidence indicates that the dicarboxylate and 2-oxoglutarate carriers serve to transport glutathione into mitochondria [59, 60] . The mitochondrial glutathione pool amounts to approximately 15% of total cellular glutathione [61] , but the mitochondrial glutathione pool plays a critical role in cytoprotection [62, 63] . Hence, strategies to increase the mitochondrial content of glutathione and other thiol-based antioxidants may serve to protect mitochondria, along with cells and organs, against oxidative damage.
Accordingly, glutathione choline ester and N-acetyl-lcysteine choline ester were prepared as mitochondrially targeted antioxidants (Fig. 5 ) (S.-S. Sheu, V.K. Sharma, D. Nauduri, L. Xu, P.S. Brookes, and M. W. Anders, unpublished work). These hydrophilic antioxidants were designed to exploit Preliminary experiments show that these compounds reduce tert-butylhydroperoxide-induced rat heart mitochondrial depolarization, delay the onset of mitochondrial depolarization caused by H 2 O 2 in neonatal rat ventricular myocytes (Fig. 6 ) and striatal neurons, and diminish N-methyl-d-aspartate (NMDA)-induced ROS generation in striatal neurons. These results demonstrate that targeting of glutathione and related thiol-based antioxidants to mitochondria is a useful approach for preventing oxidative stress-related mitochondrial dysfunction and as such may find use in the management of a range of acute and chronic disease processes.
Conclusions and perspectives
A decade of research in understanding mechanisms involved in mitochondrial dysfunction related disease states has clearly implicated overproduction of ROS. This knowledge has resulted in a range of strategies to develop mitochondrially targeted antioxidants that prevent ROS-induced mitochondrial oxidative damage. The compounds described so far show promise in a range of in vitro systems and one (MitoQ) has demonstrated activity in a rat model of cardiac ischemiareperfusion injury. Preclinical studies in intact rodent models are, however, needed to evaluate the effectiveness and toxicity of mitochondrially targeted antioxidants. These compounds do, to be sure, show that this is a fruitful avenue of investigation that may lead to clinically useful therapeutic agents.
